Researchers developed a new method to label and track #Tcells in the body using #PETimaging and engineered receptors. This could improve understanding of #celltherapy and support safer use in future treatments: http://go.tum.de/935833

#Immunotherapy

πŸ“·V. Morath

Tracking immune cells inside the body

A new procedure uses PET imaging to visualize immune cells in the body. It helps to better understand cell and gene therapies and make them safer.

Check out our lab's #newpaper in @cellpress Cell:
We found that the skull is special - its marrow is a special immunologic niche. Skull #Immune #cells can move to the meninges via skull-meninges connections, which we found both in mice and humans with #tissueclearing and #lightsheet #microscopy.
We also bring #proteomics and #PETimaging to the mix!

Paper: https://doi.org/10.1016/j.cell.2023.07.009

Explainer thread:
https://bird.makeup/users/erturklab/statuses/1689293936185991169

This has bugged me, so curious what others think:

1) test-retest variability of dopamine release by raclopride PET reported to be (on the higher end) ~10~12% https://pubmed.ncbi.nlm.nih.gov/23238524/

2) D2/D3 binding measures (raclopride, fallypride) -- TRV also up to 10% or so in some reports
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446562/

2) I've seen several papers reporting DA release and D2/D3 binding changes lower than these reported TRVs. **

*inc ones I've co-authored :(
#neuroimaging #PETimaging #neuroscience

Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride - PubMed

In the present preliminary study, the test-retest reproducibility of BP of [C]MNPA and of [C]MNPA/[C]raclopride was reliable in the caudate and putamen.

PubMed